Introduction: The Evolution of Incretin-Based Therapies
The landscape of metabolic medicine has been fundamentally reshaped over the last decade by the emergence of incretin-based therapies. From the early days of daily GLP-1 receptor (GLP-1R) agonists to the current era of once-weekly unimolecular dual agonists, the goal has remained consistent: achieving profound weight loss while optimizing glycemic control with minimal side effects. However, as the medical community looks beyond the successes of drugs like semaglutide and tirzepatide, a new frontier is emerging—signaling-biased agonism.
CT-388 represents a sophisticated step forward in this evolution. As a once-weekly, signaling-biased dual GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, CT-388 aims to refine the therapeutic window by modulating how receptors respond to stimulation at a molecular level. Recent findings published in Molecular Metabolism highlight the potent translatability of this molecule from preclinical models to human subjects, suggesting that signaling bias may be the key to unlocking even greater efficacy in treating obesity and type 2 diabetes.
